

Arlene O Siefker-Radtke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5424627/publications.pdf>

Version: 2024-02-01

133
papers

12,778
citations

31902

53
h-index

24179

110
g-index

137
all docs

137
docs citations

137
times ranked

11173
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2023, 6, 228-232.	2.6	11
2	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e16-e24.	0.9	1
3	Multimodal kidneyâ€preserving approach in localised and locally advanced highâ€risk upper tract urothelial carcinoma. <i>BJUI Compass</i> , 2022, 3, 37-44.	0.7	3
4	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 248-258.	5.1	73
5	Erdafitinib for locally advanced or metastatic urothelial carcinoma. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	0.5	0
6	Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 263-269.	0.4	7
7	Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 176-182.	0.9	5
8	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. <i>Nature Communications</i> , 2022, 13, 1797.	5.8	23
9	Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. <i>European Urology</i> , 2022, 82, 365-373.	0.9	6
10	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021, 17, 137-149.	1.1	5
11	Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2021, 79, 655-656.	0.9	1
12	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021, 127, 840-849.	2.0	51
13	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	1.5	7
14	Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. <i>Frontiers in Oncology</i> , 2021, 11, 621591.	1.3	29
15	Progression of Disease after Bacillus Calmette-GuÃ©rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1258-1267.	0.2	7
16	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. , 2021, 9, e002850.		15
17	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e2122998.	2.8	13
18	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1267.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021, 17, 3137-3150.	1.1	21
20	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. <i>Nature Communications</i> , 2021, 12, 5606.	5.8	76
21	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	0.9	741
22	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. <i>Nature Medicine</i> , 2020, 26, 1845-1851.	15.2	193
23	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. <i>IScience</i> , 2020, 23, 101201.	1.9	18
24	Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e197-e206.	1.8	10
25	Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. <i>Clinical Cancer Research</i> , 2020, 26, 5120-5128.	3.2	79
26	Emerging treatments in advanced urothelial cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 232-239.	1.1	2
27	Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2019, 381, 338-348.	13.9	885
28	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 599-603.	0.9	95
29	Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1089-1098.	1.0	20
30	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	0.8	185
31	Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 354.e19-354.e26.	0.8	4
32	Targeting advanced urothelial carcinoma-developing strategies. <i>Current Opinion in Oncology</i> , 2019, 31, 207-215.	1.1	14
33	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 95-105.	1.2	19
34	FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4511-4511.	0.8	45
35	NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.. <i>Journal of Clinical Oncology</i> , 2019, 37, 388-388.	0.8	18
36	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. <i>BJU International</i> , 2018, 122, 89-98.	1.3	28

#	ARTICLE	IF	CITATIONS
37	Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. Journal of Urology, 2018, 199, 1129-1142.	0.2	34
38	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. European Urology Focus, 2018, 4, 442-454.	1.6	10
39	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nature Reviews Urology, 2018, 15, 112-124.	1.9	73
40	Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 342-353.	1.8	20
41	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1041-1053.	2.3	171
42	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications, 2018, 9, 3503.	5.8	224
43	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Human Pathology, 2018, 79, 57-65.	1.1	48
44	Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. , 2018, , .		10
45	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA;) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T <i>FGFR</i> alterations (FGFRalt).. Journal of Clinical Oncology, 2018, 36, 4503-4503.	0.8	63
46	Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with <i>FGFR</i> mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 450-450.	0.8	13
47	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	1.2	26
48	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2017, 18, 312-322.	5.1	1,388
49	Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial Cancer. Journal of Clinical Oncology, 2017, 35, 816-817.	0.8	1
50	Optimizing management of upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 492-498.	0.8	18
51	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Pathology, 2017, 147, 500-506.	0.4	52
52	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1240-1267.	2.3	220
53	High-grade neuroendocrine carcinoma of the urachusâ”report of 3 cases. Human Pathology, 2017, 67, 126-133.	1.1	2
54	Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy, 2017, 9, 781-784.	1.0	2

#	ARTICLE	IF	CITATIONS
55	Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. <i>European Urology Focus</i> , 2017, 3, 577-583.	1.6	10
56	Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?. <i>Urology</i> , 2017, 102, 7-16.	0.5	15
57	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. <i>BJU International</i> , 2017, 119, 684-691.	1.3	36
58	Reply to B. Biswas et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2097-2097.	0.8	0
59	Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216217.	0.2	28
60	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 96-100.	1.0	5
61	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
62	Editorial Comment. <i>Journal of Urology</i> , 2016, 195, 1696-1696.	0.2	0
63	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. <i>European Urology</i> , 2016, 70, 611-620.	0.9	120
64	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. <i>EBioMedicine</i> , 2016, 12, 105-117.	2.7	257
65	A Phase I Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. <i>Molecular Therapy</i> , 2016, 24, 1484-1491.	3.7	45
66	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3346-3348.	0.8	6
67	Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. <i>Urology</i> , 2016, 89, 83-89.	0.5	17
68	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. <i>European Urology</i> , 2016, 69, 855-862.	0.9	228
69	Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 59.e1-59.e8.	0.8	51
70	Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4513-4513.	0.8	14
71	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. <i>Oncotarget</i> , 2016, 7, 80164-80174.	0.8	40
72	Urachal and Non-urachal Adenocarcinomas of the Bladder. , 2016, , 139-151.		1

#	ARTICLE	IF	CITATIONS
73	Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 218-224.	0.9	10
74	Towards effective adjuvant treatment for urothelial cancer. <i>Lancet Oncology</i> , The, 2015, 16, 9-10.	5.1	2
75	Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 377-394.	0.9	57
76	Urachal carcinoma: a pathologic and clinical study of 46 cases. <i>Human Pathology</i> , 2015, 46, 1808-1814.	1.1	78
77	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4571-TPS4571.	0.8	7
78	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014, 120, 2684-2693.	2.0	105
79	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. <i>Cancer Cell</i> , 2014, 25, 152-165.	7.7	1,358
80	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2014, 11, 400-410.	1.9	267
81	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. <i>Cancer</i> , 2014, 120, 1794-1799.	2.0	154
82	Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2014, 191, 40-47.	0.2	153
83	Abstract CT241: Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology. , 2014, ,		1
84	Frequent truncating mutations of STAG2 in bladder cancer. <i>Nature Genetics</i> , 2013, 45, 1428-1430.	9.4	164
85	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinomaâ€”Neoadjuvant and Adjuvant Settings. <i>European Urology</i> , 2013, 63, 58-66.	0.9	151
86	Plasmacytoid Urothelial Carcinoma, a Chemosensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis. <i>Journal of Urology</i> , 2013, 189, 1656-1661.	0.2	138
87	Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. <i>European Urology</i> , 2013, 64, 307-313.	0.9	147
88	Critical analysis of contemporary clinical research in muscleâ€”invasive and metastatic urothelial cancer. <i>Cancer</i> , 2013, 119, 1994-1998.	2.0	12
89	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer. <i>Cancer</i> , 2013, 119, 540-547.	2.0	74
90	The p63 Protein Isoform Î”Np63Î± Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 3275-3288.	1.6	116

#	ARTICLE	IF	CITATIONS
91	Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells. PLoS ONE, 2013, 8, e69509.	1.1	35
92	Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Canadian Urological Association Journal, 2013, 3, 228.	0.3	27
93	A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 4548-4548.	0.8	1
94	Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 311-311.	0.8	6
95	A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 263-263.	0.8	6
96	p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells. Cancer Biology and Therapy, 2012, 13, 477-486.	1.5	18
97	Perioperative chemotherapy for upper tract urothelial cancer. Nature Reviews Urology, 2012, 9, 266-273.	1.9	18
98	Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas M. D. Anderson Cancer Center experience. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 879-885.	0.8	44
99	Bladder Cancer and Upper Tracts. , 2012, , 311-333.		0
100	Urachal Adenocarcinoma: A Clinician's Guide for Treatment. Seminars in Oncology, 2012, 39, 619-624.	0.8	109
101	Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center.. Journal of Clinical Oncology, 2012, 30, 261-261.	0.8	31
102	p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. PLoS ONE, 2012, 7, e30206.	1.1	71
103	Small Cell Urothelial Carcinoma. , 2012, , 173-181.		0
104	Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy. Urology, 2011, 78, 61-67.	0.5	43
105	The role of radical cystectomy in patients with clinical T4b bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 157-161.	0.8	13
106	Bladder Cancer: Can We Move Beyond Chemotherapy?. Current Oncology Reports, 2010, 12, 278-283.	1.8	6
107	Re: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. European Urology, 2010, 57, 728-729.	0.9	1
108	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer, 2010, 116, 3127-3134.	2.0	208

#	ARTICLE	IF	CITATIONS
109	The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder. <i>Clinical Cancer Research</i> , 2010, 16, 4461-4467.	3.2	133
110	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 429-440.	0.8	188
111	Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1701-1703.	1.1	5
112	Bladder Cancer: Narrowing the Gap Between Evidence and Practice. <i>Journal of Clinical Oncology</i> , 2009, 27, 5680-5684.	0.8	56
113	Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2592-2597.	0.8	148
114	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 335-344.	2.7	324
115	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5060-5072.	3.2	386
116	Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy. <i>Urology</i> , 2009, 73, 147-152.	0.5	63
117	A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents. <i>Journal of Urology</i> , 2008, 180, 867-872.	0.2	54
118	Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells. <i>Clinical Cancer Research</i> , 2008, 14, 1478-1486.	3.2	96
119	Micropapillary bladder cancer. <i>Cancer</i> , 2007, 110, 62-67.	2.0	253
120	Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder. <i>Cancer</i> , 2007, 110, 764-769.	2.0	84
121	P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. <i>European Urology</i> , 2007, 52, 769-776.	0.9	61
122	Partial Cystectomy for Muscle Invasive Urothelial Carcinoma of the Bladder: A Contemporary Review of the M. D. Anderson Cancer Center Experience. <i>Journal of Urology</i> , 2006, 175, 2058-2062.	0.2	135
123	Uncommon Cancers of the Bladder. , 2006, , 18-26.		3
124	Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon- β for metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 107, 497-505.	2.0	14
125	Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon- β -2b. <i>Cancer</i> , 2006, 107, 2254-2261.	2.0	38
126	Systemic chemotherapy options for metastatic bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 877-885.	1.1	11

#	ARTICLE	IF	CITATIONS
127	Urachal carcinoma: surgical and chemotherapeutic options. Expert Review of Anticancer Therapy, 2006, 6, 1715-1721.	1.1	92
128	Focus on bladder cancer. Cancer Cell, 2004, 6, 111-116.	7.7	252
129	Is There a Role for Surgery in the Management of Metastatic Urothelial Cancer? The M. D. Anderson Experience. Journal of Urology, 2004, 171, 145-148.	0.2	141
130	EVIDENCE SUPPORTING PREOPERATIVE CHEMOTHERAPY FOR SMALL CELL CARCINOMA OF THE BLADDER: A RETROSPECTIVE REVIEW OF THE M. D. ANDERSON CANCER EXPERIENCE. Journal of Urology, 2004, 172, 481-484.	0.2	225
131	Neoadjuvant chemotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 464-467.	0.8	9
132	Multimodality Management of Urachal Carcinoma: The M. D. Anderson Cancer Center Experience. Journal of Urology, 2003, 169, 1295-1298.	0.2	248
133	Phase III Trial of Fluorouracil, Interferon Alfa-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer. Journal of Clinical Oncology, 2002, 20, 1361-1367.	0.8	73